Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(9), P. 1216 - 1216
Published: Sept. 17, 2024
Activating
the
cytosolic
innate
immune
sensor,
cGAS-STING
pathway,
holds
great
promise
for
enhancing
antitumor
immunity,
particularly
in
combination
with
checkpoint
inhibitors
(ICIs).
However,
clinical
application
of
STING
agonists
is
often
hindered
by
poor
tumor
accumulation,
limited
cellular
uptake,
and
rapid
clearance.
To
address
these
challenges,
we
developed
a
human
serum
albumin
(HSA)-based
nanoreactor
system
efficient
delivery
agonist
SR-717,
aiming
to
improve
its
efficacy.
Journal of Translational Medicine,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: Jan. 6, 2025
Immuno-oncology
has
witnessed
remarkable
advancements
in
the
past
decade,
revolutionizing
landscape
of
cancer
therapeutics
an
encouraging
manner.
Among
diverse
immunotherapy
strategies,
mRNA
vaccines
have
ushered
a
new
era
for
therapeutic
management
malignant
diseases,
primarily
due
to
their
impressive
impact
on
COVID-19
pandemic.
In
this
comprehensive
review,
we
offer
systematic
overview
vaccines,
focusing
optimization
structural
design,
crucial
role
delivery
materials,
and
administration
route.
Additionally,
summarize
preclinical
studies
clinical
trials
provide
valuable
insights
into
current
status
treatment.
Furthermore,
delve
discussion
significant
challenges
facing
development
tumor
vaccines.
These
encompass
both
intrinsic
external
factors
that
are
closely
intertwined
with
successful
application
innovative
approach.
To
pave
way
more
promising
future
treatments,
deeper
understanding
immunological
mechanisms,
increasing
number
high-quality
trials,
well-established
manufacturing
platform
crucial.
Collaborative
efforts
between
scientists,
clinicians,
industry
engineers
essential
achieving
these
goals.
Dentistry Journal,
Journal Year:
2025,
Volume and Issue:
13(2), P. 79 - 79
Published: Feb. 13, 2025
Background:
Recent
advances
in
mRNA
vaccine
technology,
accelerated
by
the
global
COVID-19
pandemic,
have
generated
significant
interest
their
applications
beyond
infectious
diseases.
Dentistry
has
emerged
as
a
promising
field
for
exploring
potential
of
mRNA-based
therapies
preventing
and
treating
oral
Objectives:
This
narrative
review
aims
to
evaluate
current
status
development
its
preclinical
health,
focusing
on
periodontal
disease,
dental
caries,
regenerative
medicine,
implantology,
cancer.
Methods:
The
synthesizes
findings
from
studies,
including
research
conducted
animal
models
vitro,
assess
modulate
immune
responses
promote
tissue
regeneration
cavity.
Clinical
trials
were
only
mentioned
context
broader
areas
implementation
such
oncology
immunotherapy.
Results:
studies
highlight
capacity
vaccines
enhance
body's
response
facilitate
repair
processes.
Despite
these
results,
challenges
persist
delivering
effectively
within
complex
environment.
These
include
stability,
delivery
mechanisms,
modulation
responses.
Conclusions:
While
offer
promise
revolutionizing
health
care,
they
face
notable
limitations
concerning
safety,
efficacy,
clinical
feasibility.
Overcoming
obstacles
through
further
is
essential
unlock
full
translational
ensure
safe
effective
integration
into
practice.
ChemMedChem,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 17, 2025
Abstract
Lipid
nanoparticles
(LNPs)
have
emerged
as
a
transformative
platform
for
the
targeted
delivery
of
therapeutic
agents,
revolutionizing
treatment
paradigms
across
spectrum
diseases.
Since
inception
liposomes
in
1960s,
lipid‐based
nanotechnology
has
evolved
to
address
limitations
such
poor
bioavailability,
off‐target
effects,
and
instability,
thereby
enhancing
efficacy
safety
drug
administration.
This
review
highlights
latest
advancements
LNPs
technology,
focusing
on
their
application
cancer
therapy,
gene
infectious
disease
management,
glaucoma,
other
clinical
areas.
Recent
studies
underscore
potential
deliver
messenger
RNA
(mRNA)
small
interfering
(siRNA)
precise
genetic
intervention,
exemplified
by
breakthroughs
interference
CRISPR‐Cas9
genome
editing.
Additionally,
been
successfully
employed
ameliorate
conditions,
demonstrating
versatility
addressing
both
acute
chronic
disorders.
However,
challenges
persist
concerning
large‐scale
manufacturing,
long‐term
stability,
comprehensive
evaluations.
Future
research
must
focus
optimizing
formulations,
exploring
synergistic
combinations
with
existing
therapies,
expanding
scope
treatable
The
integration
into
personalized
medicine
exploration
applications
diseases
represent
promising
avenues
further
investigation.
are
poised
play
an
increasingly
central
role
development
next‐generation
therapeutics.
Journal of Nanobiotechnology,
Journal Year:
2024,
Volume and Issue:
22(1)
Published: June 8, 2024
Abstract
Mitochondria
occupy
a
central
role
in
the
biology
of
most
eukaryotic
cells,
functioning
as
hub
oxidative
metabolism
where
sugars,
fats,
and
amino
acids
are
ultimately
oxidized
to
release
energy.
This
crucial
function
fuels
variety
cellular
activities.
Disruption
mitochondrial
is
common
feature
many
diseases,
including
cancer,
neurodegenerative
conditions
cardiovascular
diseases.
Targeting
tumor
cell
with
multifunctional
nanosystems
emerges
promising
strategy
for
enhancing
therapeutic
efficacy
against
cancer.
review
comprehensively
outlines
pathways
metabolism,
emphasizing
their
critical
roles
energy
production
metabolic
regulation.
The
associations
between
aberrant
initiation
progression
cancer
highlighted,
illustrating
how
these
disruptions
contribute
oncogenesis
sustainability.
More
importantly,
innovative
strategies
employing
nanomedicines
precisely
target
therapy
fully
explored.
Furthermore,
key
challenges
future
directions
this
field
identified
discussed.
Collectively,
provides
comprehensive
understanding
current
state
potential
nanomedicine
targeting
offering
insights
developing
more
effective
therapies.
Human Gene Therapy,
Journal Year:
2024,
Volume and Issue:
35(17-18), P. 617 - 627
Published: Aug. 14, 2024
Lipid
nanoparticles
(LNPs)
are
the
most
clinically
advanced
drug
delivery
system
for
nucleic
acid
therapeutics,
exemplified
by
success
of
COVID-19
mRNA
vaccines.
However,
their
clinical
use
is
currently
limited
to
hepatic
diseases
and
vaccines
due
tendency
accumulate
in
liver
upon
intravenous
administration.
To
fully
leverage
potential,
it
essential
understand
address
tropism,
while
also
developing
strategies
enhance
tissues
beyond
liver.
Ensuring
that
these
therapeutics
reach
target
cells
avoiding
off-target
both
efficacy
safety.
There
three
potential
targeting
strategies-passive,
active,
endogenous-which
can
be
used
individually
or
combination
nonhepatic
tissues.
In
this
review,
we
delve
into
recent
advancements
LNP
engineering
delivering
International Journal of Nanomedicine,
Journal Year:
2024,
Volume and Issue:
Volume 19, P. 3387 - 3404
Published: April 1, 2024
Abstract:
Cancer
immunotherapy
has
emerged
as
a
novel
therapeutic
approach
against
tumors,
with
immune
checkpoint
inhibitors
(ICIs)
making
significant
clinical
practice.
The
traditional
ICIs,
PD-1
and
PD-L1,
augment
the
cytotoxic
function
of
T
cells
through
inhibition
tumor
evasion
pathways,
ultimately
leading
to
initiation
an
antitumor
response.
However,
implementation
ICIs
encounters
obstacles
stemming
from
existence
immunosuppressive
microenvironment
inadequate
infiltration
CD8
+
cells.
Considerable
attention
been
directed
towards
advancing
immunogenic
cell
death
(ICD)
potential
solution
counteract
microenvironment.
This
holds
promise
in
transforming
"cold"
tumors
into
"hot"
that
exhibit
responsiveness
antitumor.
By
combining
ICD
synergistic
response
can
be
achieved.
combination
inducers
PD-1/PD-L1
is
hindered
by
issues
such
poor
targeting
uncontrolled
drug
release.
An
advantageous
presented
stimulus-responsive
nanocarrier
integrating
physicochemical
properties
inhibitors,
facilitating
precise
delivery
specific
tissues
for
optimal
therapy.
Moreover,
these
nanocarriers
leverage
distinct
features
accomplish
controlled
release
regulate
kinetics
delivery.
article
aims
investigate
advancement
co-delivery
utilizing
inhibitors.
Special
focus
dedicated
exploring
advantages
recent
advancements
this
system
enabling
inducers.
molecular
mechanisms
are
concisely
summarized.
In
conclusion,
we
examine
research
prospects
challenges
could
greatly
enhance
immunotherapeutic
approaches
cancer
treatment.
Keywords:
therapy,
death,
co-delivery,
immune-checkpoint
Current Issues in Molecular Biology,
Journal Year:
2024,
Volume and Issue:
46(10), P. 11548 - 11579
Published: Oct. 16, 2024
Interleukin-12
(IL-12)
is
considered
to
be
a
promising
cytokine
for
enhancing
an
antitumor
immune
response;
however,
recombinant
IL-12
has
shown
significant
toxicity
and
limited
efficacy
in
early
clinical
trials.
Recently,
many
strategies
delivering
tumor
tissues
have
been
developed,
such
as
modifying
IL-12,
utilizing
viral
vectors,
non-viral
cellular
vectors.
Previous
studies
found
that
the
fusion
of
with
extracellular
matrix
proteins,
collagen,
factors
way
enhance
its
therapeutic
potential.
In
addition,
demonstrated
vectors
are
good
platform,
variety
viruses
oncolytic
viruses,
adenoviruses,
poxviruses
used
deliver
IL-12—with
testing
previously
conducted
various
cancer
models.
The
local
expression
tumors
based
on
delivery
avoids
systemic
while
inducing
effective
immunity
acting
synergistically
other
therapies
without
compromising
safety.
lipid
nanoparticles
currently
most
mature
drug
system.
Moreover,
cells
also
carriers
because
they
can
effectively
substances
tumors.
this
article,
we
will
systematically
discuss
anti-tumor
effects
own
or
combination
different
strategies.
